Men B dosing recommendations have changed

Men B dosing recommendations have changed

ACIP recommends TRUMENBA in a 2-dose schedule for healthy adolescents

The Advisory Committee on Immunization Practices (ACIP) now recommends a 2-dose schedule of TRUMENBA for healthy adolescents and young adults.

Previously, the ACIP recommended a 3-dose schedule. The 3-dose schedule is now only recommended for people at an increased risk for meningococcal disease or in an outbreak situation.

Dosing information

2-dose schedule, for healthy people aged 16 to 23 years who are not at increased risk for meningococcal disease:

  • Dose 1: administer at month 0
  • Dose 2: administer no sooner than 6 months after Dose 1

3-dose schedule, for people who are age 10 or over, and in an outbreak situation or at increased risk for meningococcal disease:

  • Dose 1: administer at month 0
  • Dose 2: administer 1-2 months after Dose 1
  • Dose 3: administer no sooner than 6 months after Dose 1

Further Information

For more information, see:

Note: Bexsero may still  be used for any adolescent as a 2-dose series at 0 months and under 1 month. See full prescribing information from GSK.

Quadracel, a new DTap and IPV vaccine, now available

In 2015, the Food and Drug Administration licensed an additional combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine (DTaP-IPV) – Quadracel, from Sanofi Pasteur Inc.

Quadracel is now available from Vaccines For Children program. This advisory includes an overview of important information about Quadracel.

Quadracel is the second DTaP-IPV vaccine to be licensed for use for children aged 4 through 6 years in the United States. Quadracel is approved for administration as a fifth dose in the DTaP series and as a fourth or fifth dose in the IPV series in children aged 4 through 6 years who have received 4 doses of DTaP-IPV-Hib (Pentacel, Sanofi Pasteur) and/or DTaP (DAPTACEL, Sanofi Pasteur) vaccine. Please note that this vaccine is not licensed for use in the primary series, for children younger than 4 years of age or older than 6 years of age.

RECOMMENDATIONS FOR USE

Eligible Groups for Receipt of VFC Supplies of Quadracel

VFC supplies of Quadracel may be given to VFC-eligible children aged 4 years through 6 years. It is approved for use as the fifth dose in the DTaP immunization series and the fourth or fifth dose in the polio immunization series.

Licensed Dosing Schedule  

Quadracel is recommended for routine immunization to be given as a booster administered intramuscularly at ages 4 through 6 years. Please note that this vaccine is not licensed for use in the primary series, for children younger than 4 years of age or older than 6 years of age. The Advisory Committee on Immunization Practices (ACIP) recommends that whenever feasible, the same manufacturer’s DTaP brand should be used to complete the series. However, if the previous brand is unavailable or unknown, any brand may be used to complete the series. Do not defer immunization solely to wait for a specific DTaP vaccine brand to be available. Interchangeability of products is allowed and considered valid.

Storage

Quadracel should be stored at 2º to 8ºC (36º to 46ºF). Do not freeze. Product which has been exposed to freezing should not be used. Do not use after the expiration date shown on the label. Quadracel is for intramuscular use only.

How Quadracel is supplied

Quadracel is supplied in a single-dose vial in packages of 10 vials (NDC No. 49281-562-10). Quadracel does not contain a preservative. The vial stopper for this product is not made with natural latex rubber.

ORDERING AND BILLING

Quadracel is available for ordering thru the KIDS Plus IIS from today, June 14, 2017. Please contact Christine Wilson (Christine.Wilson@phila.gov or 215-685-6728) or Charma Miller (Charma.Miller@phila.gov or 215-685-6667) if you need assistance adding Quadracel to your next order.

  • CVX code: 130
  • CPT code: 90696

RESOURCES

Vaccine Information Statement (VIS) and fact sheets can be used when administering Quadracel, located at: http://www.cdc.gov/vaccines/pubs/vis/default

Product insert for Quadracel includes additional vaccine information, found at: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm439856.htm

The VFC resolutions for DTaP- and polio-containing vaccines have been updated and may be found at: https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html

Additional information on vaccines and vaccine preventable diseases can be found at: http://www.cdc.gov/vaccines/

Delays in Varivax shipments

There are slight delays to Varivax shipments: Merck recently transitioned to a new warehouse for shipping vaccines and are experiencing more delays than expected.

Despite these delays, Merck expects to ship Varivax orders within the 15-day timeframe required for CDC VFC vaccine.

Thank you for your patience.

 

What’s New: March 2017 Update

What’s New highlights key information and changes to immunization requirements in Philadelphia.

This edition of What’s New includes:

  • New temperature log and digital data logger requirements
  • New school vaccination requirements
  • New dosage recommendations for HPV and Serogroup B Meningococcal vaccines
  • And more!

Click here to see the full newsletter.